These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 16355343)
1. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Zimmermann AE; Pizzoferrato T; Bedford J; Morris A; Hoffman R; Braden G Clin Infect Dis; 2006 Jan; 42(2):283-90. PubMed ID: 16355343 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Hall AM; Hendry BM; Nitsch D; Connolly JO Am J Kidney Dis; 2011 May; 57(5):773-80. PubMed ID: 21435764 [TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002 [TBL] [Abstract][Full Text] [Related]
4. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. Ryom L; Mocroft A; Kirk O; Worm SW; Kamara DA; Reiss P; Ross M; Fux CA; Morlat P; Moranne O; Smith C; Lundgren JD; J Infect Dis; 2013 May; 207(9):1359-69. PubMed ID: 23382571 [TBL] [Abstract][Full Text] [Related]
5. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336 [TBL] [Abstract][Full Text] [Related]
6. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. Gupta SK AIDS Patient Care STDS; 2008 Feb; 22(2):99-103. PubMed ID: 18260800 [TBL] [Abstract][Full Text] [Related]
8. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC; AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568 [TBL] [Abstract][Full Text] [Related]
9. Association of tenofovir exposure with kidney disease risk in HIV infection. Scherzer R; Estrella M; Li Y; Choi AI; Deeks SG; Grunfeld C; Shlipak MG AIDS; 2012 Apr; 26(7):867-75. PubMed ID: 22313955 [TBL] [Abstract][Full Text] [Related]
12. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Labarga P; Barreiro P; Martin-Carbonero L; Rodriguez-Novoa S; Solera C; Medrano J; Rivas P; Albalater M; Blanco F; Moreno V; Vispo E; Soriano V AIDS; 2009 Mar; 23(6):689-96. PubMed ID: 19262355 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S; Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673 [TBL] [Abstract][Full Text] [Related]
14. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Lucas GM; Ross MJ; Stock PG; Shlipak MG; Wyatt CM; Gupta SK; Atta MG; Wools-Kaloustian KK; Pham PA; Bruggeman LA; Lennox JL; Ray PE; Kalayjian RC; Clin Infect Dis; 2014 Nov; 59(9):e96-138. PubMed ID: 25234519 [TBL] [Abstract][Full Text] [Related]
16. Dysregulation of the mRNA Expression of Human Renal Drug Transporters by Proinflammatory Cytokines in Primary Human Proximal Tubular Epithelial Cells. Tsang YP; Hao T; Mao Q; Kelly EJ; Unadkat JD Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399338 [TBL] [Abstract][Full Text] [Related]
17. Antiviral and Antibacterial Sulfated Polysaccharide-Chitosan Nanocomposite Particles as a Drug Carrier. Yin AY; Xu J; Yang CS; Hsu SH Molecules; 2023 Feb; 28(5):. PubMed ID: 36903350 [TBL] [Abstract][Full Text] [Related]
18. Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment. Atencio P; Conesa-Buendía FM; Cabello-Ubeda A; Llamas-Granda P; Pérez-Tanoira R; Prieto-Pérez L; Álvarez BÁ; Acosta IC; Arboiro-Pinel R; Díaz-Curiel M; Largo R; Herrero-Beaumont G; Górgolas M; Mediero A Curr HIV Res; 2021; 19(5):434-447. PubMed ID: 34353266 [TBL] [Abstract][Full Text] [Related]
19. Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use. Rao M; Dadey L; Glowa T; Veldkamp P Infect Dis Rep; 2021 May; 13(2):448-453. PubMed ID: 34073672 [TBL] [Abstract][Full Text] [Related]
20. Tenofovir-induced osteomalacia with hypophosphataemia. Iatan I; Lee TC; McDonald EG BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34031073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]